Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient took the first three capsules of Vivotif on time and forgot about the 4th dose; Case reference number US-BN-2025-001693 is a spontaneous case initially received from a nurse via Bavarian Nordic (reference number: CASE-000322) on 17-Oct-2025 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number and expiration date: unknown), at an unknown dose, route or site of administration for an unknown indication. On an unspecified date, unknown amount of time from the first dose, the patient took the second dose of Vivotif (batch number and expiration date: unknown) at an unknown dose, route or site of administration. On an unspecified date, unknown amount of time from the first dose, the patient took the third dose of Vivotif (batch number and expiration date: unknown) at an unknown dose, route or site of administration. As reported, the patient took the first three capsules of Vivotif on time and forgot about the fourth dose (explicitly coded as 'missed dose'). The patient was due to have her fourth dose on 04-Oct-2025. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information's were provided.; Reporter's Comments: A spontaneous case concerning a patient of unknown age and gender reported a non-serious event of missed dose, which occurred when the patient took the first three capsules of Vivotif on time but product dose omission issue, which was due on 04-Oct-2025. No adverse events were reported in association with Vivotif administration. At the time of the initial report, it was unknown if the patient experienced any adverse event due to the missed dose. Product dose omission issue is assessed as not related to suspect vaccine but to human factor. The case was assessed as non-serious.; Sender's Comments: A spontaneous case concerning a patient of unknown age and gender reported a non-serious event of missed dose, which occurred when the patient took the first three capsules of Vivotif on time but product dose omission issue, which was due on 04-Oct-2025. No adverse events were reported in association with Vivotif administration. At the time of the initial report, it was unknown if the patient experienced any adverse event due to the missed dose. Product dose omission issue is assessed as not related to suspect vaccine but to human factor. The case was assessed as non-serious.
Comments: NONE.